• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种新型合成二氢茚并[1,2-b]吲哚衍生物(LS-2-3j)逆转了癌细胞中 ABCB1 和 ABCG2 介导的多药耐药性。

A Novel Synthetic Dihydroindeno[1,2-b] Indole Derivative (LS-2-3j) Reverses ABCB1- and ABCG2-Mediated Multidrug Resistance in Cancer Cells.

机构信息

School of Ocean, Shandong University, Weihai 264209, China.

Department of Biomedical Engineering, Faculty of Electronic Information and Electrical Engineering, Dalian University of Technology, Dalian 116024, China.

出版信息

Molecules. 2018 Dec 10;23(12):3264. doi: 10.3390/molecules23123264.

DOI:10.3390/molecules23123264
PMID:30544754
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6321174/
Abstract

10-oxo-5-(3-(pyrrolidin-1-yl) propyl)-5,10-dihydroindeno [1,2-b] indol-9-yl propionate (LS-2-3j) is a new chemically synthesized indole compound and some related analogues are known to be inhibitors (such as alectinib and Ko143) of ATP-binding cassette (ABC) transporters, especially the ABC transporter subfamily B member 1 (ABCB1) and the ABC transporter subfamily G member 2 (ABCG2). This study aimed to evaluate the multidrug resistance (MDR) reversal effects and associated mechanisms of LS-2-3j in drug-resistant cancer cells. The inhibition of cell proliferation in tested agents was evaluated by the 3-(4,5-dimethylthiazol)-2,5-diphenyltetrazolium bromide (MTT) assay. Accumulation or efflux of chemotherapy drugs was analyzed by flow cytometry. The ATPase activity was measured using an ATPase activity assay kit. The mRNA transcripts and protein expression levels were detected by real-time PCR and Western blot, respectively. In this connection, LS-2-3j significantly enhanced the activity of chemotherapeutic drugs in MDR cells and could significantly increase the intracellular accumulation of doxorubicin (DOX) and mitoxantrone (MITX) by inhibiting the function of the efflux pumps in ABCB1- or ABCG2-overexpressing cells. Furthermore, reduced ATPase activity, mRNA transcription, and protein expression levels of ABCB1 and ABCG2 were observed in a concentration dependent manner in MDR cancer cells.

摘要

10-氧代-5-(3-(吡咯烷-1-基)丙基)-5,10-二氢茚并[1,2-b]吲哚-9-基丙酸酯(LS-2-3j)是一种新合成的吲哚化合物,一些相关的类似物已知是三磷酸腺苷(ATP)结合盒(ABC)转运蛋白的抑制剂(如艾乐替尼和 Ko143),特别是 ABC 转运蛋白亚家族 B 成员 1(ABCB1)和 ABC 转运蛋白亚家族 G 成员 2(ABCG2)。本研究旨在评估 LS-2-3j 在耐药癌细胞中的多药耐药(MDR)逆转作用及其相关机制。通过 3-(4,5-二甲基噻唑)-2,5-二苯基四氮唑溴盐(MTT)测定评估测试药物对细胞增殖的抑制作用。通过流式细胞术分析化疗药物的积累或外排。使用 ATP 酶活性测定试剂盒测定 ATP 酶活性。通过实时 PCR 和 Western blot 分别检测 mRNA 转录本和蛋白质表达水平。在这方面,LS-2-3j 显著增强了 MDR 细胞中化疗药物的活性,并通过抑制 ABCB1 或 ABCG2 过表达细胞中外排泵的功能,显著增加多柔比星(DOX)和米托蒽醌(MITX)的细胞内积累。此外,在 MDR 癌细胞中观察到 ABCB1 和 ABCG2 的 ATP 酶活性、mRNA 转录和蛋白表达水平呈浓度依赖性降低。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7503/6321174/7240e5dbedfa/molecules-23-03264-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7503/6321174/d9bad472489b/molecules-23-03264-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7503/6321174/87e5848db337/molecules-23-03264-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7503/6321174/6c66fa25c078/molecules-23-03264-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7503/6321174/2dde3534c094/molecules-23-03264-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7503/6321174/9dd23a8b99ec/molecules-23-03264-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7503/6321174/027e40bc1caa/molecules-23-03264-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7503/6321174/7240e5dbedfa/molecules-23-03264-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7503/6321174/d9bad472489b/molecules-23-03264-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7503/6321174/87e5848db337/molecules-23-03264-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7503/6321174/6c66fa25c078/molecules-23-03264-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7503/6321174/2dde3534c094/molecules-23-03264-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7503/6321174/9dd23a8b99ec/molecules-23-03264-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7503/6321174/027e40bc1caa/molecules-23-03264-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7503/6321174/7240e5dbedfa/molecules-23-03264-g007.jpg

相似文献

1
A Novel Synthetic Dihydroindeno[1,2-b] Indole Derivative (LS-2-3j) Reverses ABCB1- and ABCG2-Mediated Multidrug Resistance in Cancer Cells.一种新型合成二氢茚并[1,2-b]吲哚衍生物(LS-2-3j)逆转了癌细胞中 ABCB1 和 ABCG2 介导的多药耐药性。
Molecules. 2018 Dec 10;23(12):3264. doi: 10.3390/molecules23123264.
2
Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo.FW-04-806,一种大环内酯类双内酯化合物,对 ABCB1 和 ABCG2 介导的多药耐药的体内外逆转作用。
Cell Commun Signal. 2019 Sep 1;17(1):110. doi: 10.1186/s12964-019-0408-5.
3
Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells.沃鲁西利布,一种强效的细胞周期蛋白依赖性激酶4/6(CDK4/6)抑制剂,可拮抗ABCB1和ABCG2介导的癌细胞多药耐药性。
Cell Physiol Biochem. 2018;45(4):1515-1528. doi: 10.1159/000487578. Epub 2018 Feb 19.
4
Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.拉帕替尼(泰立沙,GW572016)通过抑制ATP结合盒亚家族B成员1和G成员2的活性来逆转癌细胞中的多药耐药性。
Cancer Res. 2008 Oct 1;68(19):7905-14. doi: 10.1158/0008-5472.CAN-08-0499.
5
Derivative of 5-cyano-6-phenylpyrimidin antagonizes ABCB1- and ABCG2-mediated multidrug resistance.5-氰基-6-苯基嘧啶衍生物拮抗 ABCB1 和 ABCG2 介导的多药耐药性。
Eur J Pharmacol. 2019 Nov 15;863:172611. doi: 10.1016/j.ejphar.2019.172611. Epub 2019 Aug 30.
6
Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.达可替尼通过抑制 ABCB1 和 ABCG2 转运蛋白的外排活性来拮抗癌细胞中的多药耐药(MDR)。
Cancer Lett. 2018 May 1;421:186-198. doi: 10.1016/j.canlet.2018.01.021. Epub 2018 Jan 11.
7
Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.厄洛替尼(特罗凯,OSI-774)可拮抗ATP结合盒转运体B成员1和ATP结合盒转运体G成员2介导的耐药性。
Cancer Res. 2007 Nov 15;67(22):11012-20. doi: 10.1158/0008-5472.CAN-07-2686.
8
Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.舒尼替尼使过表达ABCG2的细胞对传统化疗药物敏感,这与抑制ABCG2的功能有关。
Cancer Lett. 2009 Jun 28;279(1):74-83. doi: 10.1016/j.canlet.2009.01.027. Epub 2009 Feb 18.
9
Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.乌利替尼(BVD-523)拮抗 ABCB1 和 ABCG2 介导的化疗药物耐药性。
Biochem Pharmacol. 2018 Dec;158:274-285. doi: 10.1016/j.bcp.2018.10.028. Epub 2018 Oct 26.
10
Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo.达可替尼通过抑制 ABCG2 的药物外排功能,在体外和体内增强常规化疗药物的疗效。
J Exp Clin Cancer Res. 2018 Feb 20;37(1):31. doi: 10.1186/s13046-018-0690-x.

引用本文的文献

1
Formulation, Characterization and Cytotoxicity Effects of Novel Thymoquinone-PLGA-PF68 Nanoparticles.新型百里醌-PLGA-PF68 纳米粒的制备、表征及细胞毒性作用。
Int J Mol Sci. 2021 Aug 30;22(17):9420. doi: 10.3390/ijms22179420.
2
Inhibitors of Human ABCG2: From Technical Background to Recent Updates With Clinical Implications.人类ABCG2抑制剂:从技术背景到近期进展及其临床意义
Front Pharmacol. 2019 Mar 5;10:208. doi: 10.3389/fphar.2019.00208. eCollection 2019.

本文引用的文献

1
The therapeutic potential of targeting ABC transporters to combat multi-drug resistance.靶向ABC转运蛋白以对抗多药耐药性的治疗潜力。
Expert Opin Ther Targets. 2017 May;21(5):511-530. doi: 10.1080/14728222.2017.1310841. Epub 2017 Apr 3.
2
Alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance in vitro, in vivo and ex vivo.艾乐替尼(CH5424802)在体外、体内和离体实验中均能拮抗ABCB1和ABCG2介导的多药耐药性。
Exp Mol Med. 2017 Mar 17;49(3):e303. doi: 10.1038/emm.2016.168.
3
The Inhibitor Ko143 Is Not Specific for ABCG2.
抑制剂Ko143对ABCG2并非特异性的。
J Pharmacol Exp Ther. 2015 Sep;354(3):384-93. doi: 10.1124/jpet.115.225482. Epub 2015 Jul 6.
4
Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update.乳腺癌耐药蛋白(BCRP/ABCG2)在药物转运中的作用——最新进展
AAPS J. 2015 Jan;17(1):65-82. doi: 10.1208/s12248-014-9668-6. Epub 2014 Sep 19.
5
Tyrosine kinase inhibitors as reversal agents for ABC transporter mediated drug resistance.酪氨酸激酶抑制剂作为ABC转运蛋白介导的耐药逆转剂。
Molecules. 2014 Sep 4;19(9):13848-77. doi: 10.3390/molecules190913848.
6
Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer.卵巢癌中紫杉醇敏感性与ABCB1表达、外排及单核苷酸多态性的关系
Sci Rep. 2014 May 9;4:4669. doi: 10.1038/srep04669.
7
Reversing multidrug resistance in Caco-2 by silencing MDR1, MRP1, MRP2, and BCL-2/BCL-xL using liposomal antisense oligonucleotides.使用脂质体反义寡核苷酸沉默MDR1、MRP1、MRP2和BCL-2/BCL-xL逆转Caco-2细胞中的多药耐药性。
PLoS One. 2014 Mar 17;9(3):e90180. doi: 10.1371/journal.pone.0090180. eCollection 2014.
8
Regulations of ABCB1 and ABCG2 expression through MAPK pathways in acute lymphoblastic leukemia cell lines.通过 MAPK 通路调控 ABCB1 和 ABCG2 在急性淋巴细胞白血病细胞系中的表达。
Anticancer Res. 2013 Dec;33(12):5317-23.
9
Changes in the expression of miR-381 and miR-495 are inversely associated with the expression of the MDR1 gene and development of multi-drug resistance.miR-381 和 miR-495 的表达变化与 MDR1 基因的表达和多药耐药的发展呈负相关。
PLoS One. 2013 Nov 26;8(11):e82062. doi: 10.1371/journal.pone.0082062. eCollection 2013.
10
ATP Binding Cassette C1 (ABCC1/MRP1)-mediated drug efflux contributes to disease progression in T-lineage acute lymphoblastic leukemia.ATP结合盒转运体C1(ABCC1/MRP1)介导的药物外排促进T系急性淋巴细胞白血病的疾病进展。
Health (Irvine Calif). 2013 May;5(5A):41-50. doi: 10.4236/health.2013.55A005.